0.125
AIM ImmunoTech Inc stock is traded at $0.125, with a volume of 223.64K.
It is up +2.21% in the last 24 hours and down -7.41% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.1223
Open:
$0.1232
24h Volume:
223.64K
Relative Volume:
0.23
Market Cap:
$8.59M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-0.2083
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-9.22%
1M Performance:
-7.41%
6M Performance:
-50.98%
1Y Performance:
-74.50%
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AIM
AIM ImmunoTech Inc
|
0.125 | 8.59M | 202.00K | -28.96M | -21.85M | -0.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan
Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada
Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India
What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock By Investing.com - Investing.com Australia
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock - Investing.com India
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
AIM ImmunoTech Inc. Appoints Principal Investigator for Clinical Study Combining Ampligen and AstraZeneca's FluMist for Influenza Vaccine Development - Nasdaq
AIM announces Paul Goepfert, MD, as the principal - GlobeNewswire
Could This $10M Avian Flu Vaccine Strategy Outperform Billion-Dollar mRNA Alternatives? - StockTitan
AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City - ACCESS Newswire
AIM ImmunoTech to Present at the Investor Summit in Philadelphia - ACCESS Newswire
AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' - ACCESS Newswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
AIM ImmunoTech Plans to Meet NYSE Compliance by 2026 Amid Cancer and Antiviral Drug Advances - HPBL
AIM ImmunoTech Eyes a Resilient Comeback with Strategic Moves to Stay Afloat - Smartphone Magazine
AIM ImmunoTech gains NYSE compliance plan approval By Investing.com - Investing.com South Africa
Biotech Trailblazer AIM ImmunoTech Charts a Resilient Path to Equity Compliance - Jomfruland.net
AIM ImmunoTech gains NYSE compliance plan approval - Investing.com
AIM ImmunoTech Secures NYSE American Compliance Plan Approval – What It Means for Investors - HPBL
AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance -February 26, 2025 at 01:37 pm EST - Marketscreener.com
AIM ImmunoTech Inc. Receives Approval from NYSE American for Compliance Plan with Listing Standards - Nasdaq
Can AIM ImmunoTech Maintain NYSE Listing? Exchange Grants Rare 2-Year Extension - StockTitan
AIM ImmunoTech Appoints David Chemerow to Board - TipRanks
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The Manila Times
Can This Former Comscore Executive Turn Around AIM ImmunoTech's Immuno-Pharma Ambitions? - StockTitan
AIM Doses First New Subject in Phase 2 Study of Ampligen - GlobeNewswire
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study - Marketscreener.com
Hemispherx Biopharma stock hits 52-week low at $0.12 By Investing.com - Investing.com South Africa
Hemispherx Biopharma stock hits 52-week low at $0.12 - Investing.com India
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):